neoplasms . Cancer Discov 2016 ; 6 : 154 – 165 . 26566875 10.1158/2159-8290.CD-15-0913 3. Badalian-Very G , Vergilio JA , Degar BA , Recurrent BRAF mutations in Langerhans cell histiocytosis . Blood 2010 ; 116 : 1919 – 1923
Search Results
Boyu Hu, Jay L. Patel, Randa Tao, Richard B. Cannon, Marcus Monroe, and Gaurav Goyal
Alan P. Venook, Maria E. Arcila, Al B. Benson III, Donald A. Berry, David Ross Camidge, Robert W. Carlson, Toni K. Choueiri, Valerie Guild, Gregory P. Kalemkerian, Razelle Kurzrock, Christine M. Lovly, Amy E. McKee, Robert J. Morgan, Anthony J. Olszanski, Mary W. Redman, Vered Stearns, Joan McClure, and Marian L. Birkeland
learning throughout the trial lifecycle. As an example of the challenges, consider the situation in which a trial required validated testing for specific BRAF mutations across a variety of tumor types. Methods available to accomplish this included
Matthew Zibelman and Anthony J. Olszanski
. Molecular testing results became available and demonstrated a V600K BRAF mutation (c.1798_1799GT>AA). The patient was referred to ophthalmology and the decision was made to proceed with the third dose of ipilimumab. Two weeks later, the patient presented
Presented by: Genevieve Boland
lymph nodes,” Dr. Boland said. Patients need to be tested for BRAF mutation status, staged appropriately, and surgically managed (wide excision, LND), with consideration given to enrolling appropriate patients in neoadjuvant trials. Adjuvant
NCCN Guidelines Insights: Rectal Cancer, Version 6.2020
Featured Updates to the NCCN Guidelines
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Alyse Johnson-Chilla, and Lisa A. Gurski
5% to 9% of CRCs are characterized by a specific mutation in the BRAF gene (V600E). 32 , 33 BRAF mutations are, for all practical purposes, limited to tumors that do not have KRAS exon 2 mutations. 32 – 34 The NCCN panel currently recommends
Scott Ramsey and Veena Shankaran
overall survival according to tumor KRAS and BRAF mutation status . J Clin Oncol 2011 ; 29 : 2011 – 2019 . 10 Douillard JY Siena S Cassidy J . Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and
John A. Thompson
trial, 675 patients with metastatic melanoma and BRAF mutation (as detected with the COBAS 4800 V600E mutation test) were randomized to vemurafenib (960 mg orally, twice daily) versus dacarbazine (1000 mg/kg every 3 weeks). 12 The hazard ratio for
Tatjana Gavrancic and Yeun-Hee Anna Park
molecularly selective settings. The targeting of the RAS/RAF/MEK/ERK pathway with clinically available surrogate markers harboring KRAS and/or BRAF mutations could be a strategy for selecting more responsive personalized cancer therapy using molecular
Joshua B. Brown, Reetesh K. Pai, Melissa A. Burgess, Jennifer Chennat, and Amer H. Zureikat
KIT gene are the most common, accounting for 80% to 85% of GIST mutations, with PDGFR α mutations representing 5% to 10% of mutations. The remaining mutations have been termed wild-type ; however, SDH and BRAF mutations have been identified
Patrick M. Lynch
from epigenetic hypermethylation of the hMLH1 promoter, and also typically showing BRAF mutation) are worth detecting because of differences in prognosis and response to adjuvant therapies that include 5-FU. 14 This is the position of the EGAPP. 15
